van Vollenhoven, R F <br/><br/>
American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: data from a 52-week phase III trial.  [electronic resource] 

 -  Arthritis care & research  Jan 2011 
 - 128-34 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2151-4658 
<br/><br/><label>Standard No.: </label>10.1002/acr.20331  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antibodies, Monoclonal, Humanized<br/>Arthritis, Rheumatoid--drug therapy<br/>Certolizumab Pegol<br/>Drug Therapy, Combination<br/>Female<br/>Humans<br/>Immunoglobulin Fab Fragments--administration & dosage<br/>Male<br/>Methotrexate--administration & dosage<br/>Polyethylene Glycols--administration & dosage<br/>Rheumatology--standards<br/>Societies, Medical--standards<br/>United States